Changes to the concentration and presentation of injectable Trastuzumab (440 mg)
Peru
19 junio 2019

On June 19, the Ministry of Health of Peru, through Ministerial Resolution No. 545-2019/MINSA, modified the concentration and presentation of injectable Trastuzumab (440 mg). This is a drug used in the treatment of HER2 positive breast cancer and is covered under the country’s National List of Essential Medicines (see page 3 of document).

The purpose of the regulations is to ensure accurate and appropriate dosage of Trastuzumab 420 mg and 440 mg in vials, for which it has been considered “necessary to modify the National List of Essential Medicines, in order to specify the concentration and presentation of the aforementioned pharmaceutical product”.

wefeqwf